The trial, sponsored by Cancer Trials Ireland, aimed to identify biomarkers predictive of response to docetaxel in patients with hormone-refractory prostate cancer. With an enrollment of 73 patients, the study's completion may provide valuable insights into the utility of mRNA as a predictive biomarker, potentially enhancing treatment personalization in this patient population. The findings could position docetaxel as a more targeted therapy, thereby improving patient outcomes and offering a competitive edge in the prostate cancer treatment market. Given the increasing focus on precision medicine, the results may attract interest from pharmaceutical companies looking to develop companion diagnostics or enhance existing therapies. The commercial implications extend to potential collaborations or licensing opportunities for biomarker development.